Background: High levels of cytokines in juvenile idiopathic arthritis (JIA) can alter target cell sensitivity to growth hormone (GH) leading to short stature in adulthood. We hypothesized that the down-regulation of GH receptor (GHR) gene expression could be involved in growth failure of children with JIA. Methods: In 18 (12 F and 6 M) prepubertal JIA patients and 13 age- and sex-matched healthy children, we evaluated serum growth-promoting factors and inflammatory indexes. We also measured GHR gene expression, by real-time PCR, in lymphocytes of patients and controls. All parameters were evaluated in patients before and after treatment of JIA. Results: The most interesting (p = 0.007) result was the increase in GHR mRNA expression in all JIA patients. Moreover, we observed a significant (p = 0.0156) decrease in IL-6 levels in JIA patients after 2 years of therapy (19.37 ± 41.01) with respect to basal values (90.84 ± 124.71). On the contrary, IGF-I significantly (p = 0.0005) increased to a mean SDS value of 0 (range -1.69 to +1.70 SDS) with respect to values at disease onset (-0.64 SDS). Conclusions: Our preliminary data suggest that the restoration of both GHR gene expression and IGF-I secretion correlate with inactive disease in JIA children.

Keywords:
Gene expression, Juvenile idiopathic arthritis, Children, Growth hormone receptor, Growth
1.
Saha MT, Verronen P, Laippala P, Lenko HL: Growth of prepubertal children with juvenile chronic arthritis. Acta Paediatr 1999;88:724-728.
2.
Souza LS, Machado SH, Brenol CV, Brenol JCT, Xavier RM: Growth velocity and interleukin-6 concentrations in juvenile idiopathic arthritis. J Rheumatol 2008;35:2265-2271.
3.
MacRae VE, Wong SC, Farquharson C, Ahmed SF: Cytokine actions in growth disorders associated with pediatric chronic inflammatory diseases. Int J Mol Med 2006;18:1011-1018.
4.
Wong SC, MacRae VE, Gracie JA, et al: Inflammatory cytokines in juvenile idiopathic arthritis: effects on physical growth and the insulin-like growth factor axis. Growth Hormone IGF Res 2008;18:369-378.
5.
Garcia-Consuegra Molina J, Merino Munoz R, Lama More R, Coya Vina J, Garcia Bouthelier R: Growth in children with juvenile idiopathic arthritis. An Pediatr (Barc) 2003;58:529-537.
6.
Simon D, Fernando C, Czernichow P, Prieur AM: Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with long-term glucocorticoids. J Rheumatol 2002;29:1296-1300.
7.
Aitman TJ, Palmer RG, Loftus J, et al: Serum IGF-I levels and growth failure in juvenile chronic arthritis. Clin Exp Rheumatol 1989;7:557-561.
8.
Flores-Morales A, Greenhalgh CJ, Norstedt G, Rico-Bautista E: Negative regulation of growth hormone receptor signalling. Mol Endocrinol 2006;20:241-253.
9.
Petty RE, Southwood TR, Manners O, Baum J, et al: International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol 2004;31:390-392.
10.
Wang SJ, Yang YH, Lin YT, Yang CM, Chiang BL: Attained adult height in juvenile rheumatoid arthritis with or without corticosteroid treatment. Clin Rheumatol 2002;21:363-368.
11.
Guszczyn T, Rzeczycka J, Popko J: IGF-I and IGF-binding proteins in articular exudates of children with post-traumatic knee damage and juvenile idiopathic arthritis. Pathobiology 2009;76:260-266.
12.
Mircic M, Kavanaugh A: Inhibition of IL-6 in rheumatoid arthritis and juvenile idiopathic arthritis. Exp Cell Res 2011;317:1286-1292.
13.
Bechtold S, Ripperger P, Muhlbayer D, et al: GH therapy in juvenile chronic arthritis: results of a two-year controlled study on growth and bone. J Clin Endocrinol Metab 2001;86:5737-5744.
14.
Bechtold S, Ripperger P, Dalla Pozza R, et al: Growth hormone increases final height in patients with juvenile idiopathic arthritis: data from a randomized controlled study. J Clin Endocrinol Metab 2007;92:3013-3018.
15.
Walsh N: Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005;208:228-251.
16.
Alonzi T, Fattori E, Lazzaro D, et al: Interleukin-6 is required for the development of collagen-induced arthritis. J Exp Med 1998;187:461-468.
17.
Sasai M, Saeki Y, Ohshima S, et al: Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum 1999;42:1635-1643.
18.
Takagi N, Mihara M, Moriya Y, et al: Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998;41:2117-2121.
19.
Allen RC, Jimenez M, Cowell CT: Insulin-like growth factor and growth hormone secretion in juvenile chronic arthritis. Ann Rheum Dis 1991;50:602-606.
20.
Bechtold S, Roth J: Natural history of growth and body composition in juvenile idiopathic arthritis. Horm Res 2009;72:13-19.
21.
Hattori N: Expression, regulation and biological actions of growth hormone and ghrelin in the immune system. Growth Horm IGF Res 2009;19:187-197.
22.
Shearer WT, Rosenblatt HM, Gelman RS, et al: Lymphocyte subsets in healthy children from birth through 18 years of age: The Pediatric AIDS Clinical Trials Group P1009 Study. J Allergy Clin Immunol 2003;112:973-980.
23.
Amit T, Moussa Youdim BH, Hochberg Z: Does serum growth hormone binding protein reflect human GH receptor function? J Clin Endocrinol Metab 2000;85:927-932.
24.
Bresson JL, Jeay S, Gagnerault MC, et al: Growth hormone (GH) and prolactin receptors in human peripheral blood mononuclear cells: relation with age and GH-binding protein. Endocrinology 1999;140:3203-3209.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.